March 24, 2022SHILAP Revista de lepidopterología42 citationsOpen Access

Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

XZXiao ZhangCapital Medical University ZYZhengyang YangCapital Medical University YAYongbo AnHankyong National University

Key Points

Key points are not available for this paper at this time.

Abstract

We have registered this study in the International Prospective Register of Systematic Reviews (PROSPERO), and the registration number is CRD42021249601 .

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Zhang et al. (2022) studied this question.

synapsesocial.com/papers/69d74dbdb54ccf0cfef30cd1 https://doi.org/10.1186/s12957-022-02549-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012 · 12,806 citations
2Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer2020 · 109 citations
3Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-1642019 · 1,033 citations
4Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial.2020 · 35 citations
5Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)2020 · 943 citations

AI से पूछें

Bookmark

View Full Paper